126 related articles for article (PubMed ID: 36074787)
1. Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment.
Gray JR; Kehoe LG; Peckham AM; Wakeman SE
J Addict Med; 2023 Mar-Apr 01; 17(2):227-229. PubMed ID: 36074787
[TBL] [Abstract][Full Text] [Related]
2. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G
Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report.
Barrett J; Schapiro R; Casey E; Chertok J
J Addict Med; 2024 Mar-Apr 01; 18(2):209-211. PubMed ID: 38227854
[TBL] [Abstract][Full Text] [Related]
5. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
[TBL] [Abstract][Full Text] [Related]
6. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
[No Abstract] [Full Text] [Related]
7. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
[TBL] [Abstract][Full Text] [Related]
8. Extended-release buprenorphine outcomes among treatment resistant veterans.
Cotton AJ; Lo K; Kurtz FB; Waldbauer L
Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
[No Abstract] [Full Text] [Related]
9. Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
J Addict Med; 2019; 13(6):442-449. PubMed ID: 30844878
[TBL] [Abstract][Full Text] [Related]
10. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting.
Wong JSH; Masson S; Huang A; Romm D; Fong M; Porter T; Sharifi N; Azar P; Mathew N
J Correct Health Care; 2022 Dec; 28(6):368-371. PubMed ID: 36342953
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
Jones AK; Ngaimisi E; Gopalakrishnan M; Young MA; Laffont CM
Clin Pharmacokinet; 2021 Apr; 60(4):527-540. PubMed ID: 33135125
[TBL] [Abstract][Full Text] [Related]
13. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.
Hansen ER; South AM; Lofwall MR; Fanucchi LC
J Addict Med; 2024 Jan-Feb 01; 18(1):65-67. PubMed ID: 37874645
[TBL] [Abstract][Full Text] [Related]
14. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
[TBL] [Abstract][Full Text] [Related]
15. Use of long-acting injectable buprenorphine in the correctional setting.
Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
[TBL] [Abstract][Full Text] [Related]
16. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
[TBL] [Abstract][Full Text] [Related]
17. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
Lai M; Bowman J; Charles J; Smid MC
J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
[TBL] [Abstract][Full Text] [Related]
18. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
19. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2022 Feb; 100():103492. PubMed ID: 34736130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
